Prokarium Secures $10 Million Investment from Saudi, Swedish and Korean Investors for Clinical Development of Revolutionary Thermostable Vaccines
Summary
KEELE, England & RIYADH, Saudi Arabia & STOCKHOLM, Sweden & SEOUL, South Korea--(BUSINESS WIRE)--Prokarium, the UK-based synthetic biology company that has developed Vaxonella, an oral, thermostable vaccine delivery platform, today announced the completion of a $10 million investment round. Korea Investment Partners (KIP) is South Korea’s largest venture capital firm operating globally from its Seoul headquarters, with other offices in Shanghai, Beijing, and Silicon Valley. Prokarium’s CEO, Dr Ted Fjallman, commented: “The vaccine industry and the synthetic biology community in the UK are thriving and our team has worked hard to play a central role in both, winning several prestigious grants and government contracts. Currently the focus is on preventing Chlamydia, Clostridium difficile, and enteric fever (typhoid and paratyphoid) as well as developing a vaccine against plague under a UK Department of Health and Social Care SBRI contract. Within the healthcare segment, RVC invests in the development of novel therapeutics and vaccines, as well as other solutions to address the growing threats of cancer, diabetes, cardiovascular diseases and obesity, diagnostics & monitoring, and medical devices.